Dexmedetomidine Hydrochloride Injection shortage (US): status and presentations
Shortage United States Β· first listed 10 April 2020 Β· updated 15 October 2026
| Dosage form | Injection |
|---|---|
| Therapy area | Anesthesia |
| Presentations | 11 unavailable, 0 limited, 45 available |
| Source | US FDA Drug Shortage Database (openFDA), checked 19 October 2026 |
Presentations affected
- Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL β Unavailable
- Dexmedetomidine Hydrochloride, Injection, 200 mcg/2 mL β Unavailable
- Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL β Unavailable
- Dexmedetomidine Hydrochloride, Injection, 200 mcg/50 mL β Available
- Dexmedetomidine Hydrochloride, Injection, 200 mcg/50 mL (4 ug/1 mL) β Available
- Dexmedetomidine Hydrochloride, Injection, 200 ug/2 mL β Available
- Dexmedetomidine Hydrochloride, Injection, 200 ug/50 mL β Available
- Dexmedetomidine Hydrochloride, Injection, 4 mcg/mL, 100 mL β Available
- Dexmedetomidine Hydrochloride, Injection, 4 mcg/mL, 50 mL β Available
- Dexmedetomidine Hydrochloride, Injection, 400 mcg/100 mL β Available
- Dexmedetomidine Hydrochloride, Injection, 400 mcg/100 mL (4 ug/1 mL) β Available
- Dexmedetomidine Hydrochloride, Injection, 400 ug/100 mL β Available
- Dexmedetomidine Hydrochloride, Injection, 80 mcg/20 mL β Available
- Precedex, Injection, 1000 mcg/250 mL β Available
- Precedex, Injection, 1000 mcg/250 mL Glass Bottle NovaPlus β Available
- Precedex, Injection, 1000 mcg/250 mL Single Dose Glass Bottle β Available
- Precedex, Injection, 200 mcg/2 mL (100 mcg/mL) β Available
- Precedex, Injection, 200 mcg/50 mL β Available
- Precedex, Injection, 200 mcg/50 mL (4 mcg/mL) β Available
- Precedex, Injection, 400 mcg/100 mL β Available
- Precedex, Injection, 400 mcg/100 mL (4 mcg/mL) β Available
- Precedex, Injection, 80 mcg/20 mL (4 mcg/mL) β Available
Strengths and packs as listed by the regulator. Manufacturer names and product codes are not shown.
What buyers can do
- Check whether other registered presentations or strengths can be used, and ask your wholesaler about allocation.
- For hospital and tender supply, look for manufacturers that already hold an approval in your market and can increase output.
- In a critical shortage, the FDA can allow temporary importation of a version approved in a well-regulated market. That decision is made by the FDA, case by case.
- Qualify any new source as carefully as at any other time: GMP certificate, registration status and a certificate of analysis for each batch.
See the product page for Dexmedetomidine Hydrochloride Injection on PharmaTradz.
More: where licensed suppliers can step in during US shortages.
Need Dexmedetomidine Hydrochloride Injection?
Send a request with your market, strength and quantity. We match licensed buyers with qualified suppliers.
Request a quote I can supply thisFollow this shortage
We email you when its status changes. Confirm first; unsubscribe any time.
Related shortages
- Lidocaine Hydrochloride Injection
- Rocuronium Bromide Injection
- Midazolam Hydrochloride Injection
- Bupivacaine Hydrochloride Injection
- Ropivacaine Hydrochloride Injection
- Atropine Sulfate Injection
- Epinephrine Bitartrate, Lidocaine Hydrochloride Injection
- Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection
For information only. Shortage status changes often; confirm with the regulator before making decisions. Brand names, where shown, are trademarks of their owners.